FIBROSTATIN S L has a total of 28 patent applications. It decreased the IP activity by 66.0%. Its first patent ever was published in 2010. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and China. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are POLARIS PHARMACEUTICALS INC, ARAD DORIT and TSUMURA & CO.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | China | 4 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Mexico | 3 | |
#6 | Hong Kong | 2 | |
#7 | Australia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Measurement | |
#5 | Foods and drinks | |
#6 | Agriculture |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Acyclic or carbocyclic compounds | |
#4 | Peptides | |
#5 | Analysing materials | |
#6 | Heterocyclic compounds | |
#7 | Enzymes | |
#8 | Animal care | |
#9 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Revert Fernando | 28 |
#2 | Revert-Ros Francisco | 27 |
#3 | Saus Juan | 24 |
#4 | Fustero Santos | 7 |
#5 | Aguado-Velasco Carmen | 6 |
#6 | Perez-Paya Enrique | 5 |
#7 | Sanz-Cervera Juan F | 5 |
#8 | Sanz-Cervera F Juan | 5 |
#9 | Blasco Raül | 4 |
#10 | Blasco Raul | 4 |
Publication | Filing date | Title |
---|---|---|
WO2017134146A1 | Gpbp inhibitors and uses and scaleable synthesis thereof | |
WO2016107906A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | |
CN105723224A | Goodpasture antigen binding protein detection and inhibition and its use in diabetes | |
WO2014006020A1 | Gpbp-1 inhibition and its therapeutic use | |
WO2012113785A1 | Methods for treating and diagnosing disease | |
CN102781898A | GPBP inhibition using Q2 peptidomimetics |